Sermorelin: A Laboratory Research Reference

Sermorelin is a synthetic peptide corresponding to the amino-terminal fragment of growth hormone-releasing hormone (GHRH). It is studied in laboratory research for its activity at the GHRH receptor and its downstream influence on growth hormone release in experimental models.

This page is a non-promotional scientific reference for researchers. It summarises the chemical identity, molecular characteristics, mechanism as described in the literature, research areas, and analytical testing of sermorelin. It does not provide dosing, therapeutic, or human-use guidance of any kind. Sermorelin supplied by Bulk Aussie Peptides is for laboratory research purposes only.

What Is Sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide identical to the first 29 residues of endogenous human growth hormone-releasing hormone (GHRH). Native GHRH is a 44-amino-acid hypothalamic peptide; the amino-terminal 29-residue fragment — often written GHRH(1–29)-NH₂ — retains the receptor-binding and activation activity of the full sequence, while the remaining carboxy-terminal residues contribute mainly to structural stability rather than receptor engagement.

Because it is a truncated analogue rather than full-length GHRH, sermorelin is a useful research tool for interrogating GHRH-receptor pharmacology independently of the native hormone. For background on how synthetic research peptides of this kind are produced and verified, see the synthetic peptides research guide.

Molecular Characteristics

Sermorelin’s identity in analytical documentation is established by several molecular properties:

• Classification: a synthetic growth hormone-releasing hormone (GHRH) analogue, a member of the GHRH-receptor agonist family.
• Sequence: a 29-amino-acid peptide representing the amino-terminal fragment of human GHRH.
• Molecular weight: reported in Daltons (Da) on product documentation; the measured value from a Certificate of Analysis should be compared against the theoretical mass derived from the sequence.
• Physical form: supplied as a lyophilised (freeze-dried) powder, the standard presentation for research peptides.

How Sermorelin Works

Sermorelin exerts its studied effects by binding to and activating the GHRH receptor, a class B G-protein-coupled receptor on anterior pituitary somatotroph cells. Activation of this receptor in laboratory models is associated with cyclic AMP signalling and the release of growth hormone, mirroring the action of endogenous GHRH.

An important analytical consideration is that the unmodified GHRH(1–29) sequence is rapidly cleaved in biological matrices, principally by the enzyme dipeptidyl peptidase-4. This is a property of the native-like sequence in experimental systems and does not constitute a therapeutic claim; it simply informs how the peptide behaves under study. Research findings in this area remain preclinical.

Areas of Scientific Research

The research literature describes several distinct lines of investigation involving sermorelin and related GHRH analogues:

• GHRH receptor pharmacology: studies characterising receptor binding and activation by the amino-terminal fragment.
• Growth hormone release: investigation of pulsatile growth hormone secretion in experimental endocrine models.
• Analogue design: work comparing native GHRH(1–29) with stabilised variants to understand structure–activity relationships.

These investigations are conducted in vitro or in approved animal research models under institutional oversight. They do not translate to approved human use.

Analytical Testing

As with other research peptides, sermorelin is characterised using complementary analytical techniques:

• HPLC for purity assessment, reported as a percentage of total peak area.
• Mass spectrometry for identity confirmation, by comparing measured molecular mass to the theoretical value.

Guidance on interpreting the resulting documents is available in the article on how to read a peptide Certificate of Analysis.

Storage and Handling

In a laboratory context, lyophilised sermorelin is typically stored in a freezer, protected from light and moisture, and handled according to the product-specific documentation. Once reconstituted, the resulting solution is refrigerated and used within the timeframe stated in the documentation. General guidance is covered in the peptide storage and stability reference.

Frequently Asked Questions

• What is sermorelin? Sermorelin is a synthetic 29-amino-acid analogue of the amino-terminal fragment of growth hormone-releasing hormone (GHRH).
• What is sermorelin studied for? It is investigated in laboratory models for GHRH-receptor pharmacology and growth hormone release.
• Is sermorelin a peptide? Yes — it is a full peptide corresponding to GHRH(1–29), not a modified fragment.
• What receptor does sermorelin target? It binds to and activates the GHRH receptor.
• How is sermorelin purity tested? Purity is commonly estimated by HPLC, while identity is confirmed by mass spectrometry.
• How does sermorelin differ from tesamorelin? Both are GHRH analogues, but tesamorelin is a further-stabilised derivative of the full 44-amino-acid sequence; see the dedicated tesamorelin reference for detail.

References

• Rivier, J., Spiess, J., Thorner, M., & Vale, W. (1982). Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature, 300(5889), 276–278. PubMed 6292724
• Frohman, L. A., & Szabo, M. (1981). Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumours associated with acromegaly. In Growth Hormone and Other Biologically Active Peptides. This and other early characterisation work established the GHRH(1–29) fragment as the receptor-active core.

Related Research Resources

• Tesamorelin: A Laboratory Research Reference — a related stabilised GHRH analogue.
• CJC-1295 with DAC: A Laboratory Research Reference — another GHRH-receptor agonist.
• Synthetic Peptides: Research Guide — how research peptides are produced and verified.